Fatty acid lipoxygenase ALOX15 inhibitors have been disclosed in a joint Teijin Pharma Ltd. and Transthera Biosciences Co. Ltd. patent. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, autoimmune disease, cancer, cardiovascular disorders, epilepsy, Parkinson’s disease and allergic rhinitis, among others.

Zhuhai United Laboratories Co. Ltd. has patented boronic acid β-lactamase inhibitors potentially useful for the treatment of bacterial infections.

Impact Therapeutics Inc. has divulged heteroaryl compounds acting as ATP-dependent RNA helicase A (DHX9) inhibitors intended for use in the treatment of cancer.

Indiana Biosciences Research Institute Inc. and Indiana University have jointly identified tyrosine-protein kinase Lyn inhibitors described as potentially useful for the treatment of Alzheimer’s disease.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for the treatment of pain, substance abuse and dependency, schizophrenia, Alzheimer’s disease and sleep disorders.

Scientists from the Korea Research Institute of Chemical Technology and Yonsei University have identified N4-(indolin-7-yl)-N2-(2-alkoxypyridin-3-yl)pyrimidine-2,4-diamine derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) mutant inhibitors and therefore reported to be useful for the treatment of cancer.

Venenum Biodesign LLC has reported new substituted phenylsulfonamides acting as 2-acylglycerol O-acyltransferase 2 (MOGAT2) inhibitors described as potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD) and obesity.

The Research Foundation of State University of New York has patented toxoids reported to be useful for the treatment of cancer.

Clinch Biosciences LLC has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of stroke, hypertension, acute kidney injury, gastrointestinal motility disorders and myocardial infarction.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered new proprotein convertase subtilisin/kexin-type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase dual inhibitors. They are described as potentially useful for the treatment of hypercholesterolemia.